Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Lancet (London, England) - 2 Mar 2002

Mallal S, Nolan D, Witt C, Masel G, Martin A M, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen F T

Abstract excerpt

BACKGROUND: The use of abacavir--a potent HIV-1 nucleoside-analogue reverse-transcriptase inhibitor--is complicated by a potentially life-threatening hypersensitivity syndrome in about 5% of cases. Genetic factors influencing the immune response to abacavir might confer susceptibility. We aimed to find associations between MHC alleles and abacavir hypersensitivity in HIV-1-positive individuals treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Dideoxynucleosides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Hypersensitivity

Share to HIV Infections

Share to HLA-B Antigens

Share to HLA-DQ Antigens

Share to HLA-DR7 Antigen

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 11888582
DOI: 10.1016/s0140-6736(02)07873-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.PMID 11888582Read ↗

ASSOCIATION BETWEEN PRESENCE OF HLA-B*5701, HLA-DR7, AND HLA-DQ3 AND HYPERSENSITIVITY TO HIV-1 REVERSE-TRANSCRIPTASE INHIBITOR ABACAVIRSemantic proximity Read ↗

Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV.Semantic proximity Read ↗

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjectsSemantic proximity Read ↗

[HLA-B*5701 and abacavir hypersensitivity reaction].Semantic proximity Read ↗

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.Semantic proximity Read ↗

HLA-B*5701 testing to predict abacavir hypersensitivitySemantic proximity Read ↗

[Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].Semantic proximity Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

Predisposition to abacavir hypersensitivity conferred by <i>HLA-B</i> * <i>5701</i> and a haplotypic <i>Hsp70-Hom</i> variantSemantic proximity Read ↗

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.Semantic proximity Read ↗

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.Semantic proximity Read ↗

Current trends in screening across ethnicities for hypersensitivity to abacavir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.